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Abstract The need for new, effective agents to treat multidrug-resistant infec-
tions continues to grow as more and more bacteria develop resistance that may
result in clinical therapeutic failure. This is particularly true for common surgical
infections, such as complicated intra-abdominal infections, which frequently
involve multiple pathogens, making therapy with a broad-spectrum antibiotic an
important treatment intervention, and also for complicated skin infections, which
often involve methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant enterococci (VRE). With treatment options limited, it has become critical
to identify antibiotics with novel mechanisms of activity. Several new drugs have
emerged as possible therapeutic alternatives: linezolid, quinupristin-dalfopristin
and most recently daptomycin have all been FDA-approved for the treatment of skin
and skin structure infections. This review examines the potential role of a new class
of investigational agents, the glycylcyclines, also recently FDA-approved and
currently under review for European licensing, in the treatment of complicated skin
infections and intra-abdominal infections. Tigecycline, the first of the glycylcy-
clines, has shown excellent activity in Phase III studies of these infections, achieving
clinical success rates ranging from 70% to 91%. Furthermore, it has a good safety
profile, suggesting it will be a clinical useful addition to current therapeutic options
for the treatment of complicated skin infections and intra-abdominal infections.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
There has been an alarming increase in the in-
cidence of Gram-positive infections, including bac-
teria such as methicillin-resistant Staphylococcus
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While vancomycin has been considered the drug
of last defence against Gram-positive multi-
drug-resistant bacteria, the late 1980s saw a rise
in vancomycin-resistant bacteria, including vanco-
mycin-resistant enterococci (VRE). More recently,
strains of vancomycin-intermediate resistant
Staphylococcus aureus (VISA) and vancomycin-
resistant Staphylococcus aureus (VRSA) have beenublished by Elsevier Ltd. All rights reserved.
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coccus aureus and Streptococcus pyogenes are of-
ten the cause of skin and skin structure
infections, ranging from mild pyodermas to compli-
cated infections, including post-surgical wound in-
fections, severe carbunculosis, and erysipelas.
Complicated skin and skin structure infections are
those involving deep wounds, such as surgical inci-
sions, bites and lacerations, major abscesses, and
infected skin ulcers. They include: complicated
cellulitis, complex abscesses requiring surgical
drainage, perirectal abscesses, surgical and trau-
matic wound infections, infected diabetic and vas-
cular ischaemic ulcers, and other skin and skin
structure infections requiring surgery or intrave-
nous (IV) antibiotic therapy.2
Complicated intra-abdominal infection remains
a potentially lethal condition. Generally, the di-
agnosis is relatively straightforward on clinical
grounds; however, hospital-acquired or post-
operative intra-abdominal infections can prove
a much more difficult problem as they are more
likely to be multi-resistant. Treatment of these
infections is challenging because of their polymi-
crobial nature, which can include both aerobic and
anaerobic species. Unlike complicated skin infec-
tions, the predominant pathogens involved in
intra-abdominal infections appear to be E. coli
among the aerobes and Bacteroides species among
anaerobes.3
The present paper examines the concerns sur-
rounding the microbiology and diagnosis of com-
plicated skin and skin structure infections and
intra-abdominal infections, and also reviews cur-
rent therapeutic options for the treatment and
management of these infections, with an emphasis
on the glycylcyclines and their efficacy in clinical
studies to date.
Skin and skin structure infections
Skin and skin structure infections are commonly
seen in surgical practice as they may be either
community-acquired or nosocomially acquired as
the result of hospitalization or surgical interven-
tion.2 They are largely caused by Gram-positive
bacteria including Staphylococcus aureus, Strepto-
coccus pyogenes, Streptococcus agalactiae, and
group C and G streptococci. Specific skin and soft
tissue infections include cellulitis, erysipelas,
furuncles, simple abscesses, wound or surgical
site infections, necrotizing fasciitis, myositis, and
gas gangrene. Complicated skin and soft tissue in-
fections involve the deep tissues such as subcuta-
neous tissues, fascia and skeletal muscle, andoften require surgical intervention and hospitaliza-
tion. Surgical site infections account for approxi-
mately 14e25% of all nosocomial infections among
hospitalized patients, which makes them the third
most common type of nosocomial infection.4,5
S. aureus is considered the most common pathogen
involved in community- and hospital-acquired
staphylococcal skin and soft tissue infections
worldwide, and is particularly prevalent among
high-risk populations such as the elderly.6,7
Penicillins and cephalosporins have for many
years been the standard care for the treatment of
Gram-positive skin and skin structure infections.8
However, the effectiveness of these traditional an-
tibacterial agents has become increasingly limited
as antimicrobial-resistant Gram-positive bacteria,
including methicillin-resistant Staphylococcus au-
reus (MRSA), have become more prevalent. Of
even greater concern is the fact that methicillin
resistance in S. aureus can be conferred on other
b-lactams and antibiotic classes, including macro-
lides, tetracyclines, lincosamides and aminoglyco-
sides, making the selection of an appropriate
antibiotic therapy even more challenging. Multi-
drug resistance and cross-resistance among
Gram-positive bacteria have been increasing at
an alarming rate.9e11 In particular, the increasing
prevalence of MRSA with respect to skin and skin
structure infections is of primary concern.12
Indeed, a methicillin-resistance rate of 34% was
reported among S. aureus isolates in the United
States between 1997 and 1999, with a methicillin-
resistance rate of approximately 30% among skin
and skin structure infection isolates.6 A more
recent study by Morgan et al. showed the propor-
tion of skin and soft tissue infections caused by
MRSA increased from 29% in 2001e2002 to 64% in
2003e2004.13
With bacterial resistance comes an increased
probability of treatment failure in patients with
complicated skin and soft tissue infections, par-
ticularly among those who have polymicrobial
infections or those who need to be treated in an
ICU setting.14 Moreover, antibiotics appropriate for
MRSA are not always used promptly because physi-
cians are reluctant to use the most potent agents
available first and the delay can result in poorer
clinical outcomes as well as increased medical re-
source use and costs.15 The increased resource use
and costs associated with the delayed treatment
of methicillin-resistant Gram-positive infections,
particularly those caused by MRSA, have been
shown to be largely due to increased length of
stay (LOS) and/or complications of therapy.16e18
Glycopeptides such as vancomycin have tradi-
tionally been the drugs of choice for the treatment
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infections or multidrug-resistant Gram-positive in-
fections. However, a decrease in vancomycin
susceptibility among organisms responsible for
skin and skin structure infections, such as entero-
cocci and staphylococci, has been widely observed
over the past several years. In addition, vancomy-
cin seems less effective than linezolid in ITU
pneumonia, and studies also suggest that the
efficacy of vancomycin in methicillin-susceptible
Staphylococcus aureus (MSSA) bactaeremia and
MSSA endocarditis may be lower than that of b-
lactam agents.19e22 The combination of increasing
resistance to vancomycin, together with the less
than optimal efficacy of the drug for methicillin-
susceptible Gram-positive bacteria, has increased
the need for newer antibiotic agents, particularly
for empiric therapy for these infections.
Newly approved options for the treatment of
skin and skin structure infections include quinu-
pristin-dalfopristin, linezolid, and most recently
daptomycin (see Table 1). Quinupristin-dalfopris-
tin is the first agent in the streptogramin class. It
is indicated for the treatment of patients with se-
rious or life-threatening infections associated with
vancomycin-resistant Enterococcus faecium bac-
taeremia and complicated skin and skin structure
infections caused by S. aureus and S. pyogenes.23
The approval was based, in part, on a randomized,
open-label, controlled clinical trial comparing qui-
nupristin-dalfopristin 7.5 mg/kg q12h IV (n ¼ 221)
with cefazolin 1 g q8h IV (n ¼ 222) in the treat-
ment of complicated skin and skin structure infec-
tions caused by suspected or confirmed MRSA.23 In
the quinupristin-dalfopristin and cefazolin groups,
113 (51%) and 120 patients (54%), respectively,
were found to be clinically evaluable. Of these pa-
tients, the success rate was 66% in the quinupris-
tin-dalfopristin group and 64% in the cefazolin
group. In another trial, quinupristin-dalfopristin
7.5 mg/kg q12h IV (n ¼ 229) was compared with
oxacillin 2 g q6h IV (n ¼ 221). 105 patients (46%)in the quinupristin-dalfopristin arm and 106
patients (48%) in the oxacillin arm were found to
be clinically evaluable, and of these the success
rate was 50% for those taking quinupristin-dalfo-
pristin and 52% for those on oxacillin therapy.23
Of interest is that quinupristin-dalfopristin has ac-
tivity against vancomycin-resistant E. faecium but
not against Enterococcus faecalis. Quinupristin-
dalfopristin has been associated with venous irrita-
tion, which can be avoided if the drug is infused
through a central line, and also with high rates of
injection site reactions and often debilitating
myalgias. It cannot be given orally, which may
also be considered a disadvantage.
Linezolid is the first drug in the oxazolidinone
class and is available in both oral and parenteral
formulations. The oral formulation is nearly 100%
bioavailable and is thus interchangeable with the
parenteral formulation.24 Linezolid is indicated in
the treatment of complicated skin and skin struc-
ture infections including diabetic foot infections
without concomitant osteomyelitis caused by S. au-
reus, S. pyogenes, and S. agalactiae. In a random-
ized, multicentre, double-blind, double-dummy
trial, 400 patients received linezolid 600 mg IV
q12h followed by 600 mg PO q12h, and 419 patients
received oxacillin 2 g IV q6h followed by dicloxacil-
lin 500 mg PO q6h.24 Two hundred and forty-five
(61%) patients in the linezolid arm and 242 patients
(58%) in the oxacillin-dicloxacillin arm were clini-
cally evaluable. Cure rates were 90% in the line-
zolid group and 85% in the oxacillin-dicloxacillin
group. The most common adverse events are nau-
sea, vomiting, diarrhoea, and headache, and cases
of linezolid resistance to VRE have been reported.
In a recently published clinical study of linezolid
versus vancomycin in patients with surgical site in-
fections24 significantly more patients who had
MRSA isolated were microbiologically cured (87%
vs 48%, p ¼ 0.002) in the linezolid arm of the study.
Daptomycin is the most recently licensed addi-
tion to our therapeutic options and also representsTable 1 Antibiotics currently approved for the treatment of skin infections caused by MRSA
Class Year
approved
Formulation Dosage Major adverse
events
Vancomycin Glycopeptide 1956 IV 1 g, q12h Red man syndrome
(infusion rate)
Quinupristinedalfopristin Streptogramin 1999 IV 7.5 mg/kg, q8-12h Arthralgias/myalgias
(>20%); injection site
reactions (10e70%)
Linezolid Oxazolidinone 2000 IV, PO 600 mg, q12h Marrow suppression
(dose and duration)
Daptomycin Cyclic
lipopeptide
2003 IV 400 mg, qd Myopathy (dose
related)
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Clinical trials showed good results in skin and soft
tissue infections.26 Adult patients with clinically
documented complicated skin and skin structure
infections were enrolled in two randomized, multi-
national, multicentre, investigator-blinded stud-
ies. One study was conducted primarily in the
United States and South Africa,26 and the other
was conducted at non-US sites only.25 A total of
534 patients received daptomycin 4 mg/kg IV
q24h and 558 patients received the comparator
drug, which consisted of either vancomycin 1 g
q12h or a semisynthetic penicillin (i.e. nafcillin,
oxacillin, cloxacillin, flucloxacillin; 4e12 g IV per
day). In the first study, success rates in the clini-
cally evaluable population were 76% (158/208) in
the daptomycin group and 77% (158/206) in the
comparator group. In the second study, clinical
success rates in the clinically evaluable population
were 89% (214/238) in patients taking daptomycin
and 91% (226/250) in those treated with compara-
tor drugs. However, the failure rate of daptomycin
was excessive in a controlled trial for community-
acquired pneumonia. The most common adverse
events included gastrointestinal disorders, general
disorders (i.e. injection site reactions, fever), and
nervous system disorders.
Of the new agents in development, the glycyl-
cyclines and in particular tigecycline show much
promise. Tigecycline is the first of a new synthetic
class of antibiotics engineered to overcome the
bacterial mechanisms of resistance that have
rendered the tetracycline class increasingly
less effective.27 It has an extended broad spectrum
of activity that includes activity against most
methicillin-susceptible and -resistant Gram-
positive organisms, as well as activity against key
Gram-negative pathogens, with an MIC range of
0.015e1 mg/ml.27e29 It demonstrated no cross-
resistance with tetracycline or with other classes
of antimicrobial agents in a study by Biedenbach
et al.,30 which suggests this new glycylcycline has
potential therapeutic value for infections caused
by organisms resistant to tetracycline and tetracy-
cline derivatives. Clinical data with tigecycline in
the treatment of complicated skin and skin struc-
ture infections and in the treatment of complic-
ated intra-abdominal infections in hospitalized
patients are given later in this review.
Intra-abdominal infections
Intra-abdominal infection is defined as infection
arising from movement of microorganisms from
any part of the gastrointestinal (GI) tract toanother, usually sterile, area within the abdo-
men.31 These infections occur as a result of GI
trauma, intrinsic GI disease, or surgical resection
of the GI tractdperforated appendices and diver-
ticulitis being among the most common causes.3
Intra-abdominal infection rarely occurs as a result
of upper GI trauma because this region of the GI
tract contains few microorganisms. By contrast,
the large bowel is densely populated with both
aerobic and anaerobic bacteria.3 Intra-abdominal
infection encompasses both bacterial peritonitis
and intra-abdominal abscesses. These infections
share a common microbial aetiology, and both
are treated similarly in terms of antibiotic therapy
and the need for surgical intervention. Peritonitis
is defined as inflammation of the peritoneum that
is due to a bacterial infection. Peritonitis can
occur spontaneously, that is, without an obvious
source of bacteria. However, this is far less com-
mon than secondary peritonitis, which can occur
as a result of a lesion (such as a bowel perfora-
tion), obstruction, or operative contamination.32
Primary (or spontaneous) peritonitis tends to
occur in patients who have hepatic ascites, as well
as those at risk for nephrotic syndrome. In many
cases, the source of infection is thought to be
bacteraemia and, in fact, many patients with
primary peritonitis have a simultaneous bacterae-
mia with the same organism. Translocation of
bacteria across the gut wall has also been sug-
gested as a source of primary peritonitis.
Primary peritonitis should be suspected in pa-
tients with ascites who present with acute symp-
toms, including abdomen tenderness, fever, and
leucocytosis. Because up to 30% of patients will
lack tenderness and have a normal temperature,
a culture is needed for a definite diagnosis of
primary peritonitis. Awhite cell count of 500 cells/ml
can be a useful indicator to begin empiric antibiot-
ics. The mortality rate associated with primary
peritonitis is greater than 50%, which reflects the
severe underlying disease that is the backdrop to
this syndrome.32
Contamination of the peritoneal cavity as a re-
sult of damage to the gastrointestinal wall is
a cause of secondary peritonitis and intra-abdom-
inal abscess. As bacteria and other gut contents
are released into the peritoneum, an inflammatory
response is elicited. This response includes the
release of humoral inflammatory mediators, as
well as the recruitment of macrophages and poly-
morphonuclear leucocytes to the site of contam-
ination. If the level of contamination is low, the
host immune response may be able to clear it in its
entirety. If the inflammatory response succeeds in
confining the process to the immediate locality of
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will ensue if the level of contamination is so high
that the initial inflammatory response is over-
whelmed. In this event, there are immediate
systemic consequences, which lead to severe
symptoms. The history from patients presenting
with peritonitis includes nausea, abdominal pain,
diarrhoea or constipation, fever, and chills. Once
peritonitis has been diagnosed, surgical interven-
tion is required.33
It can be difficult to diagnose intra-abdominal
abscess because it is walled-off and localized.
Thankfully, due to advances in modern surgery,
the incidence of intra-abdominal abscess as a post-
operative complication has been documented to
be only 2%.34 As with most intra-abdominal infec-
tions, which must be corrected surgically or
by percutaneous drainage, all intra-abdominal
abscesses must be drained. Approximately 25% of
abscesses will require a second procedure regard-
less of the initial methods employed.
It is not surprising that the microbiology of
intra-abdominal infections is complicated given
that the contents of the gastrointestinal tract
have been shown to contain more than 1011 organ-
isms per gram, which are made up of more than
400 different bacterial species. It is of interest to
note that, of these, only 15 species account for
90% of the isolates cultured.35
In a susceptibility study by Aldridge et al. that
focused on clinical anaerobic isolates from four
large US medical centres,36 the authors found that
piperacillin-tazobactam was the only antibiotic
tested to which all 556 isolates were susceptible.
The resistance rates among the B. fragilis group
to ampicillin-sulbactam and clindamycin were
11% and 29%, respectively, which the authors felt
warrant concern.
Because of the large number of potential in-
fecting organisms, and the fact that culture and
susceptibility results can take 48 h to become
available, all initial antibiotic therapy is empirical.
Both facultative aerobes and anaerobes are com-
mon causes of infection and, for this reason, com-
plete coverage can be difficult to achieve.
Although the anatomical site of origin of the
infection is often a useful predictor of the organ-
isms involved in intra-abdominal infections, this is
frequently complicated by concomitant medica-
tion. For example, patients undergoing surgery for
acid-related disorders are likely to be co-medicated
with antisecretory drugs such as H2-receptor
antagonists or proton pump inhibitors. Coloniza-
tion of the stomach by Gram-negative organisms
is pH-dependent, occurring primarily at pH  4.
Consequently, by raising the intragastric pH,antisecretory agents could increase the risk of
Gram-negative intra-abdominal infection.37
Because intra-abdominal infections are nearly
always polymicrobial in nature, standard antimi-
crobial regimens generally include combination
therapy with an aminoglycoside plus an anti-
anaerobic agent (e.g., metronidazole, which has
virtually 100% activity against anaerobes or clinda-
mycin), or monotherapy with an agent that has
a broad spectrum of activity that includes activity
of anaerobes (e.g. imipenem-cilastatin). Updated
treatment guidelines from both the IDSA (Infec-
tious Disease Society of America) and the Surgical
Infection Society were published in 2003 and 2002,
respectively.38,39 Recommended single agents now
include second-generation cephalosporins with an-
aerobic coverage, b-lactam/b-lactamase inhibitor
agents, and carbapenems (imipenem/cilastatin,
meropenem, and ertapenem). Recommended com-
bination regimens include cefuroxime or a third- or
fourth-generation cephalosporin plus an anti-
anaerobic agent (either clindamycin or metronida-
zole), aztreonam plus clindamycin, ciprofloxacin
plus metronidazole, or an aminoglycoside plus an
anti-anaerobe (Table 2). It is likely that other
agents will be added to this list in the future as
prospective trials of newer agents are completed
and published.
The published literature provides little guidance
in selecting a specific regimen. However, the
combination of gentamicin with clindamycin or
metronidazole is considered by many to be the
gold standard empiric intravenous therapy for
intra-abdominal infections. Many surgeons also
choose to add ampicillin for enterococci coverage.
Table 2 Antimicrobial therapeutic options for the
treatment of intra-abdominal infections 38
Single agent Ampicillin/sulbactam
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
Ertapenem
Imipenem/cilastatin
Meropenem
Cefoxitin
Cefotetan
Combination
regimen
Gentamicin, tobramycin,
netilmicin, or amikacin
plus an anti-anaerobe
(clindamycin or metronidazole)
Cefuroxime plus metronidazole
Cefotaxime, ceftriaxone or
cefepime, each in combination
with metronidazole
Ciprofloxacin plus metronidazole
Adapted from Solomkin et al.38
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with a relatively high incidence of nephrotoxicity
and ototoxicity (10e25% and 12%, respectively).40
Imipenem/cilastatin IV monotherapy also ap-
pears to achieve clinical and bacteriological out-
comes similar to those obtained with standard
aminoglycoside regimens.41 However, it should be
noted that imipenem/cilastatin is contraindicated
in patients who are known to be hypersensitive to
b-lactam agents. In addition, this drug has been
shown to cause seizures in some patients and should
therefore be administered with caution to patients
with pre-existing CNS disorders or renal failure.
Role of glycylcyclines
Future antibiotics will need to be active broadly,
not just against ‘‘the usual suspects’’, but also
against new strains, particularly those with re-
sistance.42 The glycylcyclines, in particular tigecy-
cline, the first of the class, are showing promise in
this regard. All members of the class circumvent
the known tetracycline resistance mechanisms,
and tigecycline has exhibited a broad spectrum
of antibacterial activity against organisms such
as MRSA, VRE and ESBL (extended-spectrum
b-lactamase)-producing Enterobacteriaceae.43
Unlike most of the agents with activity against
the multidrug-resistant Gram-positive cocci, tige-
cycline retains potent in vitro activity against
multidrug-resistant Gram-negative bacteria, with
most MICs  2 mg/ml. Unfortunately, in vitro
studies suggest Pseudomonas aeruginosa and the
Proteus spp. are not well covered, primarily due
to non-specific efflux mechanisms.44 However,
Acinetobacter spp. and Stenotrophomonas malto-
philia, although not common causes of skin infec-
tions, are pathogens considered to be some of
the most recalcitrant of the Gram-negative spec-
trum, and are well covered by the tigecycline
spectrum of activity.45
A study, led by Postier, to assess the clinical
efficacy of tigecycline in hospitalized patients with
possibly life-threatening, complicated skin and
skin structure infections gave promising results.46
The infections involved deeper soft tissue or re-
quired significant surgery and included: infected
ulcers (35%), burns, or bites; major abscesses
(31%); superficial infections or abscesses with
a high risk of infection by anaerobic or Gram-
negative bacteria. In the study, 85% of patients
who received 50 mg doses of tigecycline were
cured at the end of their 7e14-day treatment,
and 74% were cured at the test-of-cure visit (the
study’s primary outcome measure), about 21 daysafter their initial dose of tigecycline. Similarly,
78% of patients treated with the 25 mg doses
were cured at the end of treatment, and 67% at
the test-of-cure visit. The decrease from 78% to
67% is a reflection of patients receiving either
additional antibiotics or surgery between the end
of treatment and test-of-cure visits. The 50 mg
group also had a higher overall bacterial eradica-
tion rate at the end of therapy, 74%, compared
to 62% for those treated with the 25 mg dose. At
the test-of-cure visit, the rates were 70% and
56%, respectively.
Similarly, tigecycline was shown to be safe and
efficacious in a randomized, double-blind, con-
trolled study of 546 patients with complicated skin
and skin structure infections that compared tige-
cycline to the combination of vancomycin and
aztreonam.47 Clinical response in the tigecycline
and combination vancomycin and aztreonam
groups was similar in the clinically evaluable mod-
ified intent-to-treat (c-mITT) population (84.3%
[95% CI 79.3, 88.5] vs 86.9% [82.1, 90.7], p ¼
0.4755) and the clinically evaluable (CE) popula-
tion (89.7% [84.9, 93.3] vs 94.4% [90.4, 97.1],
p ¼ 0.1015). Microbiological eradication occurred
in 84.8% [78.3, 89.9] of patients receiving tigecy-
cline and 93.2% [87.9, 96.7] of patients receiving
vancomycin and aztreonam. The number of pa-
tients reporting adverse events was similar in the
two groups, with increased nausea and vomiting
rates in the tigecycline group and increased inci-
dence of rash and increases in ALT/AST levels in
the combination vancomycin and aztreonam
group. Sacchidanand et al. also examined the
safety and efficacy of tigecycline compared to
that of vancomycin/aztreonam in patients with
complicated skin and skin structure infections
(cSSSI).48 Eligible patients were hospitalized adults
with cSSSIs that involved deep soft tissue (includ-
ing extensive cellulites at least 10 cm in width or
length), required surgical intervention, or was as-
sociated with significant underlying disease (e.g.,
diabetes mellitus, peripheral vascular disease,
peripheral neuropathy, or lower venous insuffi-
ciency). In addition to the infection, the patient
had to have at least two of the following signs
and symptoms: drainage or discharge, fever,
erythema, swelling, localized warmth, pain, and/
or white cell count of >10,000 cells/mm3. In
this study, cure rates were again similar between
the two groups (82.9% tigecycline vs 82.3%
vancomycin/aztreonam). Microbiological eradica-
tion rates were also similar between the two
groups (78.3% tigecycline versus 77.0% vancomycin/
aztreonam). Tigecycline was shown to have
good activity against anaerobic pathogens. All
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hibited by 2 mg/ml tigecycline. The frequency of
adverse events was also similar between the two
groups. Patients who were treated with tigecycline
had a higher incidence of nausea, vomiting, dys-
pepsia, and anorexia, while increased ALT/SGPT,
pruritis and rash occurred significantly more often
in vancomycin/aztreonam-treated patients.
Two Phase III clinical studies have been com-
pleted to date that compare tigecycline with
imipenem/cilastatin for the treatment of intra-
abdominal infection.49,50 In these trials, patients
were stratified by disease severity and randomly
assigned to tigecycline or imipenem/cilastatin
for 5e14 days. For the microbiologically evaluable
patients, the clinical responses at test-of-
cure (12e44 days after therapy) were 80.6%
(199/247) for tigecycline vs 82.4% (210/255) for imi-
penem/cilastatin (95% CI 8.4, 5.1; p < 0.001).
Corresponding clinical cure rates for the microbio-
logically modified intent-to-treat (m-mITT) popu-
lations were 73.5% (227/309) for tigecycline vs
78.2% (244/312) for imipenem/cilastatin (95% CI
11.0, 2.5; p < 0.001). A similar safety and toler-
ability profile was apparent for the two groups,
with the most commonly reported adverse events
for tigecycline and imipenem/cilastatin being nau-
sea (31.0% and 24.8%) and vomiting (25.7% and
19.4%).49 In the second study, the primary diagno-
ses were complicated appendicitis (41%), cholecys-
titis (22%), and intra-abdominal abscess (11%).
Clinical cure rates at the test-of-cure were 91.3%
for tigecycline and 89.9% for imipenem/cilastatin
(95% CI 4.0, 6.8; p < 0.001). The most commonly
reported adverse events in this study were nausea
(17.6% tigecycline vs 13.3% imipenem/cilastatin;
p ¼ 0.100) and vomiting (12.6% tigecycline vs
9.2% imipenem/cilastatin; p ¼ 0.144).50 Tigecy-
cline has not yet been evaluated as prophylactic
therapy for these infections.
Summary
Complicated skin and skin structure infections and
intra-abdominal infections each present surgeons
with a number of severe challenges. These infec-
tions occur increasingly as a result of multidrug-
resistant Gram-positive pathogens, including
MRSA, and new strategies to combat such infec-
tions are urgently needed. Complicated intra-
abdominal infections are challenging to treat
because of their polymicrobial nature and their
potential for accompanying complications and
for the risk of death. For most episodes, antimi-
crobial therapy is initially empiric and involvesa combination approach to ensure coverage of
both aerobic and anaerobic organisms. Tigecy-
cline, the first of a new class of antibacterial
agents called glycylcyclines, has shown excellent
activity against methicillin-susceptible and -resis-
tant Gram-positive organisms and against key
Gram-negative facultative bacteria commonly as-
sociated with intra-abdominal infection. Its mini-
mum inhibitory concentration (MIC90) values have
been shown to be significantly lower than those
for vancomycin, quinupristin-dalfopristin and line-
zolid against clinically important Gram-positive
and -negative aerobic bacteria including most En-
terobacteriaceae (including ESBL-producing
strains), Staphylococcus aureus and Enterococcus
spp. Clinical trial data to date have shown it
to be clinically efficacious and to have a good safe-
ty profile, so that there is justifiable optimism
about its continued clinical use and about the
development of other glycylcyclines.
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